J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):HSR24-165. doi: 10.6004/jnccn.2023.7149.
NO ABSTRACT
PMID:38579876 | DOI:10.6004/jnccn.2023.7149
Recent Content
- Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
- Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’
- Future Perspectives in Multiple Myeloma
- Patients and Caregivers Aim to Raise Funds for Myeloma Research
- GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
- Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
- Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
- Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
- Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact
- SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors